These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9831470)

  • 21. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.
    Sasaki N; Fukatsu R; Tsuzuki K; Hayashi Y; Yoshida T; Fujii N; Koike T; Wakayama I; Yanagihara R; Garruto R; Amano N; Makita Z
    Am J Pathol; 1998 Oct; 153(4):1149-55. PubMed ID: 9777946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease?
    Haley RW; Dietschy JM
    Arch Neurol; 2000 Oct; 57(10):1410-2. PubMed ID: 11030791
    [No Abstract]   [Full Text] [Related]  

  • 23. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.
    Wisniewski T; Castaño EM; Golabek A; Vogel T; Frangione B
    Am J Pathol; 1994 Nov; 145(5):1030-5. PubMed ID: 7977635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ApoE immunoreactivity and microglial cells in Alzheimer's disease brain.
    Uchihara T; Duyckaerts C; He Y; Kobayashi K; Seilhean D; Amouyel P; Hauw JJ
    Neurosci Lett; 1995 Jul; 195(1):5-8. PubMed ID: 7478253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An ApoE-Abeta inhibition complex in Abeta fibril extension.
    Wood SJ; Chan W; Wetzel R
    Chem Biol; 1996 Nov; 3(11):949-56. PubMed ID: 8939715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits.
    Yao J; Petanceska SS; Montine TJ; Holtzman DM; Schmidt SD; Parker CA; Callahan MJ; Lipinski WJ; Bisgaier CL; Turner BA; Nixon RA; Martins RN; Ouimet C; Smith JD; Davies P; Laska E; Ehrlich ME; Walker LC; Mathews PM; Gandy S
    J Neurochem; 2004 Aug; 90(4):1011-8. PubMed ID: 15287908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apolipoprotein E is associated with islet amyloid and other amyloidoses: implications for Alzheimer's disease.
    Chargé SB; Esiri MM; Bethune CA; Hansen BC; Clark A
    J Pathol; 1996 Aug; 179(4):443-7. PubMed ID: 8869295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's beta-amyloid fibril formation in vitro.
    Naiki H; Gejyo F; Nakakuki K
    Biochemistry; 1997 May; 36(20):6243-50. PubMed ID: 9166797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation.
    Castillo GM; Lukito W; Wight TN; Snow AD
    J Neurochem; 1999 Apr; 72(4):1681-7. PubMed ID: 10098877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is beta-amyloid fibrillogenesis a strict process of deposition inherently interactive in molecular terms?
    Agius LM
    Med Hypotheses; 2003 Aug; 61(2):292-6. PubMed ID: 12888321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. APOE and cholesterol homeostasis in Alzheimer's disease.
    Leduc V; Jasmin-Bélanger S; Poirier J
    Trends Mol Med; 2010 Oct; 16(10):469-77. PubMed ID: 20817608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease.
    Gearing M; Rebeck GW; Hyman BT; Tigges J; Mirra SS
    Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9382-6. PubMed ID: 7937774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue transglutaminase-catalysed cross-linking induces Apolipoprotein E multimers inhibiting Apolipoprotein E's protective effects towards amyloid-beta-induced toxicity.
    de Jager M; Drukarch B; Hofstee M; Brevé J; Jongenelen CA; Bol JG; Wilhelmus MM
    J Neurochem; 2015 Sep; 134(6):1116-28. PubMed ID: 26088696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ApoE: crossroads between Alzheimer's disease and atherosclerosis.
    Stojakovic T; Scharnagl H; März W
    Semin Vasc Med; 2004 Aug; 4(3):279-85. PubMed ID: 15630629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis.
    McLaurin J; Darabie AA; Morrison MR
    Ann N Y Acad Sci; 2002 Nov; 977():376-83. PubMed ID: 12480775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible link between lipid metabolism and cerebral amyloid angiopathy in Alzheimer's disease: A role for high-density lipoproteins?
    Mulder M; Terwel D
    Haemostasis; 1998; 28(3-4):174-94. PubMed ID: 10420065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype.
    Lippa CF; Smith TW; Saunders AM; Hulette C; Pulaski-Salo D; Roses AD
    Neurology; 1997 Feb; 48(2):515-9. PubMed ID: 9040748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apolipoprotein E4 and beta amyloid in senile plaques and cerebral blood vessels of aged rhesus monkeys.
    Poduri A; Gearing M; Rebeck GW; Mirra SS; Tigges J; Hyman BT
    Am J Pathol; 1994 Jun; 144(6):1183-7. PubMed ID: 8203459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E.
    Fan J; Donkin J; Wellington C
    Biofactors; 2009; 35(3):239-48. PubMed ID: 19472365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxidative balance in Alzheimer's disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid-β.
    Tayler H; Fraser T; Miners JS; Kehoe PG; Love S
    J Alzheimers Dis; 2010; 22(4):1363-73. PubMed ID: 20930272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.